The study is by Dr Pavel Škrha, Charles University, Prague, Czech Republic and colleagues.
New-onset diabetes mellitus/prediabetes with duration of less than 2 years can be the earliest symptom of pancreatic cancer (PAC), especially when significant weight loss is present.
Also, long-term diabetes (T2DM) is a risk factor for developing PAC.
In this study, the authors’ aim was to determine the sensitivity and specificity of the current biochemical marker CA 19-9 alone or together with promising new markers microRNA-196 and -200 in distinguishing PAC patients from non-cancer patients. Read more . . .